In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: A national survey

International Journal of Antimicrobial Agents

Volumn 20, Issue 3, 2002, Pages 186-195

  Decousser, J W ^a   Allouch, P Y ^a   Courvalin, P ^b   Leclercq, R ^c  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b INSTITUT PASTEUR   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

In vitro activity; Moxifloxacin; Respiratory tract pathogens

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; FRANCE; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HOSPITAL LABORATORY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; DATA COLLECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; FRANCE; GENES, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 0036710298     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00161-9     Document Type: Article

References (38)

1. Klugman K. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:1990;171-196.
2. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J. Antimicrob. Chemother. 38:(Suppl. A):1996;117-132.
3. Alexander Project, Schito G.C., Manelli S., Pesce A. Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J. Chemother. 9:(Suppl. 3):1997;18-28.
4. Felmingham D., Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the alexander project 1992-1996. J. Chemother. 11:(Suppl. 1):1992;5-21.
5. Fluit A.C., Schmitz F.J., Jones M.E., et al. Antimicrobial resistance among community-acquired pneumonia isolates in europe: first results from the sentry antimicrobial surveillance program. Int. J. Infect. Dis. 3:1999;153-156.
6. Chomarat M, Résistance du pneumocoque aux antibiotiques: Résultats portant sur 19 observatoires pour l'année 1999, Presse Med 2001;1, Hors série, 5-6.
7. Doern G.V., Brueggeman A.B., Huynh H., Wingert E., Rhomberg P. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998. Emerg. Infect. Dis. 5:1999;757-765.
8. Sentry Participants Group, Schmitz F.J., Verhoef J., Fluit A.C. Comparative activity of 27 antimicrobial compounds against 698 streptococcus pneumoniae isolates originating from 20 european university hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 18:1999;450-453.
9. Doern G.V., Brueggeman A.B., Holley H.P., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the united-states during the winter months of 1994-1995: results of a 30 center national surveillance study. Antimicrob. Agents. Chemother. 40:1996;1208-1213.
10. Thornsberry C., Jones M.E., Hickey M., Mauriz Y., Kahn J., Sahm D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States, 1997-1998. J. Antimicrob. Chemother. 44:2000;749-759.
11. Sahm D.F., Jones M.E., Hickey M.L., Diakun D.R., Mani S., Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J. Antimicrob. Chemother. 45:2000;457-466.
12. Masterton R.G. New quinolones: their role in clinical practice. Hosp. Med. 60:1999;82-83.
13. SPAR study group, Richard M.P., Aguado A., Mattina R., Marre R. Sensitivity to sparfloxacin and other antibiotics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis strains isolated from adults with community-acquired lower respiratory tract infections: a european multicentre study. J. Antimicrob. Chemother. 41:1998;207-214.
14. Blondeau J.M. A review of the comparative in vitro activities of 12 antimicrobial agents, with focus on five new respiratory quinolones. J. Antimicrob. Chemother. 43:(Suppl. B):1999;1-11.
15. Woodcock J.M., Andrews J.M., Boswell N.P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents. Chemother. 41:1997;101-106.
16. Comité de l'Antibiogramme de la Société Française de Microbiologie. 1996 report of Comité de l'Antibiogramme de la Société Française de Microbiologie. Technical recommandations for in vitro susceptibility testing. Clin. Microbiol. Infect. 1996;2SI:11-25.
17. Comité de l'Antibiogramme de la Société Française de Microbiologie. http://www.sfm.asso.fr. [last accessed 10th August 2001).
18. Soussy CJ, Andremont A, Cavallo JD, et al. In vitro antibacterial activity of moxifloxacin against hospital isolates and proposal for breakpoints: A multicenter study. 39th ICAAC, September 1999; abstract 372.
19. Jorgensen J.H., Weigel L.M., Ferraro M.J., Swensson J.M., Tenover F.C. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC and parE loci. Antimicrob. Agents. Chemother. 43:1999;425-427.
20. Doern G.V., Pfaller M.A., Kugler K., Freeman J., Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in north america: results from the sentry antimicrobial surveillance program. Antimicrob. Agents Chemother. 27:1997;764-770.
21. The Canadian Respiratory Infection Study Group, Zhanel G.G., Karlowski J.A., Palatnick L., Vercaigne L., Low D.E., Hoban D.J. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a canadian national surveillance study. Antimicrob. Agents Chemother. 43:1999;2504-2509.
22. Alexander Project Collaborative Group, Goldstein F.W., Acar J.F. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-1993 western europe and USA collaborative surveillance study. J. Antimicrob. Chemother. 38:(Suppl. A):1996;71-84.
23. Butler D.L., Gagnon R.C., Miller L.A., Poupard J.A., Felmingham D., Gruneberg R.N. Differences between the activity of penicillin, amoxycillin, and co-amoxiclav against 5252 Streptococcus pneumoniae isolates tested in the alexander project 1992-1996. J. Antimicrob. Chemother. 43:1999;777-782.
24. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin. Infect. Dis. 24:(Suppl. 1):1997;5-8.
25. Goldstein F.W., Garau J. 30 years of penicillin-resistant Streptococcus pneumoniae: myth or reality. Lancet. 350:1997;233-234.
26. Doit C., Loukil C., Fitoussi F., Geslin P., Bingen E. Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxycillin. Antimicrob. Agents Chemother. 43:1999;1480-1483.
27. Vergnaud M., Prevost J.N., Malbruny B., Brun J., Leclercq R. Isolation in France of a clinical strain of Streptococcus pneumoniae susceptible to amoxicillin and resistant to cefotaxime. Clin. Microbiol. Infect. 6:2000;283-284.
28. Figueirdo A.M., Connor S.J.D., Severin A., Vitoria M., Pato V., Tomasz A. A pneumococcal isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob. Agents Chemother. 36:1992;886-889.
29. Johnson A.P., Warner M., George R.C., Livermore D.M. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from england and wales. J. Antimicrob. Chemother. 47:2001;411-445.
30. Jones M.E., Staples A.M., Critchley I., et al. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. a european multi-centre study. Diagn. Microbiol. Infect. Dis. 37:2000;203-211.
31. Reinert R.R., Schlaeger J.J., Lutticken R. Moxifloxacin: a comparison with other antimicrobial agnets of in vitro activity against Streptococcus pneumoniae. J. Antimicrob. Chemother. 42:1998;803-806.
32. Souli M., Wennersten C.B., Eliopoulos G.M. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int. J. Antimicrob. Agents. 10:1998;23-30.
33. Buxbaum A., Straschil U., Moser C., Graninger W., Georgopoulos A. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates austrian bacterial surveillance network. J. Antimicrob. Chemother. 43:(Suppl. B):1999;13-18.
34. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in canada. canadian bacterial sureveillance network. New Engl. J. Med. 341:1999;233-239.
35. Jones M.E., Sahm D.F., Martin N., et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:2000;462-466.
36. Dabernat H. Sensibilité d'Haemophilus influenzae aux bêta-lactamines. Presse. Med. 2001; Hors série 1:21-2.
37. Biedenbach DJ, Jones RN, Dipersio J, Kugler KC, Wilke W. Fluoroquinolone resistance in H. influenzae and M. catarrhalis: frequency of occurrence and strain characteristics in the sentry antimicrobial surveillance program 1997-1998; north america (1999). In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 54, p. 141. American Society for Microbiology: Washington, DC.
38. Biedenbach D.J., Jones R.N. Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the sentry antimicrobial surveillance program (North and Latin America). Diagn. Microbiol. Infect. Dis. 36:2000;255-259.